Trial Information

Summary: New Oral Investigational Treatment for Relapsing-Remitting Multiple Sclerosis

Teva Pharmaceuticals is currently enrolling patients in two global research studies (Allegro and Bravo) to explore the efficacy and tolerability of a new investigational oral treatment, called laquinimod, for relapsing-remitting multiple sclerosis (RRMS).

To learn more about the studies and determine if you are eligible, visit www.TevaClinicalTrials.com or call 1-866-550-0614 (Monday through Friday, 8:00 a.m. – 5:00 p.m. Central Time).

You may be eligible to participate if you:

• Are between 18 and 55 years old
• Have a confirmed diagnosis of RRMS

This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials.

Trial listings updated: June 1, 2008 at 6:43:58 AM